Acute Kidney Injury Clinical Trials in Houston, Texas

4 studies are recruiting for acute kidney injury in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

    QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. The purpose of this surveillance registry is to prospectively collect safety data among all patients…

    Stage
    Not phased
    Ages
    Up to 22
    Site
    Texas Children's Hospital, Houston, Texas
    Locations
    15 in total
    Run by
    SeaStar Medical

    See if you can join NCT06517810 on ClinicalTrials.gov

  2. Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

    This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas
    Locations
    3 in total
    Run by
    Hope Biosciences LLC

    See if you can join NCT06654193 on ClinicalTrials.gov

  3. Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients

    The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Hermann Texas Medical Center, Houston, Texas
    Run by
    The University of Texas Health Science Center, Houston

    See if you can join NCT06531642 on ClinicalTrials.gov

  4. Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)

    The central hypothesis of this research study is that perioperative administration of the proton pump inhibitor (PPI) pantoprazole could reduce the development of acute kidney injury (AKI) following cardiac surgery by activation molecular pathways for kidney protection. The investigators propose a …

    Stage
    Phase 2
    Ages
    18 to 90
    Site
    Memorial Hermann Texas Medical Center, Houston, Texas
    Run by
    The University of Texas Health Science Center, Houston

    See if you can join NCT06706258 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.